Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G(1)–S Cell-Cycle Transition

Targeting HER2 has become a landmark in the treatment of HER2-driven breast cancer. Nonetheless, the clinical efficacy of anti-HER2 therapies can be short-lived and a significant proportion of patients ultimately develop metastatic disease and die. One striking consequence of oncogenic activation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingwei, Pearson, Adam J., Sabherwal, Nitin, Telfer, Brian A., Ali, Nisha, Kan, Karmern, Xu, Qiuping, Zhang, Wei, Chen, Fuhui, Li, Shiyang, Wang, Jinhua, Gray, Nathanael S., Risa-Ebrí, Blanca, Finegan, Katherine G., Cross, Michael J., Giurisato, Emanuele, Whitmarsh, Alan J., Tournier, Cathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613885/
https://www.ncbi.nlm.nih.gov/pubmed/36466034
http://dx.doi.org/10.1158/2767-9764.CRC-21-0089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613885/
https://www.ncbi.nlm.nih.gov/pubmed/36466034
http://dx.doi.org/10.1158/2767-9764.CRC-21-0089

Ejemplares similares